Long-Chain Carboxychromanols and Analogs are Anti-Inflammatories

Long-chain carboxychromanols and related compounds offer a therapeutic alternative to inhibit inflammation pathways, potentially treating chronic diseases.

The immune system plays a central role in maintaining health and disease development, but excessive immune response leads to inflammation. Proinflammatory mediators play important roles in regulating inflammatory response. Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2), and 5-lipoxygenase (5-LOX) play key roles in inflammatory responses; they are believed to be important in the development of degenerative disease as well.

Purdue University researchers have identified several vitamin E metabolites that act as potent inhibitors of COX-1 and COX-2, resulting in decreased inflammation. In addition, these long-chain carboxychromanols inhibit 5-LOX. Because these compounds inhibit the inflammation response through multiple pathways, they are useful anti-inflammatory agents and should have decreased side effects. Targeting COX-1, COX-2, and 5-LOX will result in a more potent anti-inflammatory effect than current nonsteroidal anti-inflammatory drugs. These compounds have potential use as effective cancer prevention and therapeutic agents, and in other chronic diseases, e.g., cardiovascular disease.

Advantages:

- -More potent anti-inflammatory effect
- -Decreased side effects
- -Other potential uses

Potential Applications:

- -Medical/Healthcare
- -Pharmaceuticals

Technology ID

64885

Category

Pharmaceuticals/Drug Discovery & Development Pharmaceuticals/Biopharmaceuti

Authors

Richard Gibbs Qing Jiang Markus Lill

Further information

Raquel Peron rperon@prf.org

View online



-Cancer Treatment

TRL: 2

Intellectual Property:

Provisional-Patent, 2007-09-26, United States | Provisional-Patent, 2008-09-19, United States | Utility Patent, 2009-09-17, United States | PCT-Patent, 2009-09-17, WO | NATL-Patent, 2009-09-17, Australia | NATL-Patent, 2009-09-17, Canada | CIP-Patent, 2014-08-29, United States | CIP-Patent, 2017-06-08, United States

Keywords: Long-chain carboxychromanols, carboxychromanol analogs, anti-inflammatories, anti-inflammation, vitamin E metabolites, cyclooxygenase inhibitors, COX inhibitors, 13'-carboxychromanol, anti-cancer agents, novel therapeutics, Cancer Therapy, Inflammatory Disease, Medical/Health, Nutrition, Pharmaceuticals, Treatment Methods